Zhangzhou Pientzehuang Pharmaceutical (600436) H1 2024 earnings summary

Executive summary

• Revenue for H1 2024 reached ¥5.65 billion, up 12.00% year-over-year; net profit attributable to shareholders was ¥1.72 billion, up 11.73% year-over-year.

• Gross margin for the period was 44.83%, with basic and diluted EPS at ¥2.85, both increasing 11.76% year-over-year.

• The company maintained its leading position in the Chinese pharmaceutical industry, with continued expansion in pharmaceuticals, distribution, and cosmetics.

• No interim dividend or capital increase from reserves was proposed for the half-year period.

• No material risks or events affecting ongoing operations were identified during the reporting period.

Financial highlights

• Operating income rose to ¥5.65 billion, a 12.00% increase compared to H1 2023; net profit attributable to shareholders was ¥1.72 billion, up 11.73%.

• Net cash flow from operating activities was ¥381 million, down 72.13% year-over-year due to increased raw material purchases.

• Total assets at June 30, 2024, were ¥17.05 billion, with shareholders’ equity at ¥13.67 billion.

• Gross margin was 44.83%, and weighted average ROE was 12.10%, down 0.63 percentage points year-over-year.

• Non-recurring items reduced net profit by ¥29.70 million, mainly due to government subsidies and fair value changes.

Outlook and guidance

• The company will continue to focus on high-quality growth, innovation, and market expansion in pharmaceuticals and cosmetics.

• Strategic investments in R&D, new product development, and digital transformation are expected to drive future growth.

• Ongoing monitoring of policy, tax, and raw material risks, with proactive measures to mitigate potential impacts.